Brad Canino
Stock Analyst at Guggenheim
(3.69)
# 602
Out of 5,114 analysts
23
Total ratings
55%
Success rate
9.74%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Brad Canino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CBIO Crescent Biopharma | Initiates: Buy | $35 | $10.15 | +245.00% | 1 | Jan 21, 2026 | |
| GLTO Galecto | Maintains: Buy | $32 → $36 | $25.79 | +39.59% | 2 | Dec 8, 2025 | |
| BDTX Black Diamond Therapeutics | Downgrades: Neutral | n/a | $2.63 | - | 2 | Dec 4, 2025 | |
| NUVL Nuvalent | Maintains: Buy | $125 → $155 | $102.32 | +51.49% | 2 | Nov 18, 2025 | |
| PYXS Pyxis Oncology | Maintains: Buy | $5 → $7 | $1.56 | +348.72% | 2 | Nov 4, 2025 | |
| KYMR Kymera Therapeutics | Assumes: Buy | $90 | $73.91 | +21.77% | 1 | Nov 3, 2025 | |
| SMMT Summit Therapeutics | Reiterates: Buy | $40 | $15.40 | +159.74% | 2 | Oct 22, 2025 | |
| CGON CG Oncology | Initiates: Buy | $90 | $53.42 | +68.48% | 1 | Oct 8, 2025 | |
| OLMA Olema Pharmaceuticals | Initiates: Buy | $20 | $26.06 | -23.25% | 1 | Oct 8, 2025 | |
| CELC Celcuity | Initiates: Buy | $110 | $112.12 | -1.89% | 1 | Sep 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $18 | $10.76 | +67.29% | 1 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $15 | $7.71 | +94.55% | 1 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $1.96 | +308.16% | 1 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $72 | $13.83 | +420.61% | 1 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $8.22 | - | 1 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $22.38 | +145.76% | 1 | Mar 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $42.28 | -29.04% | 2 | Mar 31, 2021 |
Crescent Biopharma
Jan 21, 2026
Initiates: Buy
Price Target: $35
Current: $10.15
Upside: +245.00%
Galecto
Dec 8, 2025
Maintains: Buy
Price Target: $32 → $36
Current: $25.79
Upside: +39.59%
Black Diamond Therapeutics
Dec 4, 2025
Downgrades: Neutral
Price Target: n/a
Current: $2.63
Upside: -
Nuvalent
Nov 18, 2025
Maintains: Buy
Price Target: $125 → $155
Current: $102.32
Upside: +51.49%
Pyxis Oncology
Nov 4, 2025
Maintains: Buy
Price Target: $5 → $7
Current: $1.56
Upside: +348.72%
Kymera Therapeutics
Nov 3, 2025
Assumes: Buy
Price Target: $90
Current: $73.91
Upside: +21.77%
Summit Therapeutics
Oct 22, 2025
Reiterates: Buy
Price Target: $40
Current: $15.40
Upside: +159.74%
CG Oncology
Oct 8, 2025
Initiates: Buy
Price Target: $90
Current: $53.42
Upside: +68.48%
Olema Pharmaceuticals
Oct 8, 2025
Initiates: Buy
Price Target: $20
Current: $26.06
Upside: -23.25%
Celcuity
Sep 22, 2025
Initiates: Buy
Price Target: $110
Current: $112.12
Upside: -1.89%
Sep 4, 2025
Assumes: Buy
Price Target: $18
Current: $10.76
Upside: +67.29%
Sep 4, 2025
Assumes: Buy
Price Target: $15
Current: $7.71
Upside: +94.55%
Sep 4, 2025
Initiates: Buy
Price Target: $8
Current: $1.96
Upside: +308.16%
Sep 4, 2025
Initiates: Buy
Price Target: $72
Current: $13.83
Upside: +420.61%
Sep 4, 2025
Initiates: Neutral
Price Target: n/a
Current: $8.22
Upside: -
Mar 31, 2021
Initiates: Outperform
Price Target: $55
Current: $22.38
Upside: +145.76%
Mar 31, 2021
Initiates: Outperform
Price Target: $30
Current: $42.28
Upside: -29.04%